🇺🇸 FDA
Patent

US 11534439

Dihydroquinoxaline and dihydropyridopyrazine derivatives as RSV inhibitors

granted A61KA61K31/498A61K31/4985

Quick answer

US patent 11534439 (Dihydroquinoxaline and dihydropyridopyrazine derivatives as RSV inhibitors) held by Enanta Pharmaceuticals, Inc. expires Mon Dec 22 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Enanta Pharmaceuticals, Inc.
Grant date
Tue Dec 27 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 22 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
21
CPC classes
A61K, A61K31/498, A61K31/4985, A61K45/06, A61P